Previous 10 | Next 10 |
CureVac (CVAC) -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd (CRTD) -17% after proposing stock offeringNovan (NOVN) -14% after proposing capital raise.Torchlight Energy Resources (TRCH)...
Christian Kaspar-Bartke/Getty Images News CureVac (CVAC) continues to trade sharply lower in early trading today with a ~45.4% loss after the company announced a setback for its messenger-RNA-based COVID-19 vaccine candidate in a large Phase 2b/3 study. The failure has prompted...
Matthias Hangst/Getty Images News CureVac (CVAC) has lost ~54.7% in extended trading after the company announced an efficacy of 47% for its COVID-149 vaccine candidate based on results of the second interim analysis of the Phase 2b/3 study. The international trial involving nearly 4...
Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent At second interim analysis, statistical success criteria not met. Favorable safety profile confirmed Initial analyses show trend f...
CVAC's COVID-19 vaccine may not be reviewed by regulatory authorities until August. The market was expecting CVAC to provide its pivotal data readout this month. Chatter suggests its data may have complications. CVAC's vaccine may not be available for Germany's current vaccination...
Healthcare sector and Real Estate Select Sector SPDR ETF (XLRE) gain of 1.92% and 1.88% respectively during the week outpaced S&P 500 gain of +0.40%.Looking at larger stocks (over $2B market capitalization), far and away the sector's top gainer was "meme stock" favorite ...
Orphazyme (ORPH) -49% Orphazyme stock losing half its value premarket, after rocketing fourfold the day beforeCVR Energy (CVI) -18%.Curis (CRIS) -13% on updated data for CA-4948 in blood cancers.Galecto (GLTO) -16%.Aptose Biosciences (APTO) -15% presents highlights from EH...
libre de droit/iStock via Getty Images Earlier, the German daily, Augsburger Allgemeine reported that CureVac ([[CVAC]] -1.5%) has suffered a setback in its late-stage clinical trials for the COVID-19 vaccine due to lack of infections in the control group. In reaction, Evercore ISI with ...
This article will explain some of the science that Moderna has developed behind their mRNA-based vaccines, including the COVID-19 vaccine. Moderna's platform research investments, digital backbone + manufacturing plants, and structured data collection are competitive advantages. M...
Gainers: Clover Health Investments CLOV +70%, Precipio PRPO +15%, GBS (GBS) +15%, PDS Biotechnology PDSB +15%, Cyclerion Therapeutics CYCN +10%.Losers: Ra Medical Systems RMED -19%, HOOKIPA Pharma HOOK -15%, AC Immune (ACIU...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...